Yuzhuo Wang

List of Publications by Year
in descending order

218 papers	15,309 citations	13827 67 h-index	22102 113 g-index
226 all docs	226 docs citations	226 times ranked	19818 citing authors

#	Article	IF	Citations
1	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725
2	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature, 2015, 518, 422-426.	13.7	545
3	Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell, 2010, 17, 535-546.	7.7	452
4	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
5	The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. Journal of Cellular Physiology, 2008, 215, 593-602.	2.0	346
6	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.4	304
7	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€"Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
8	Cell differentiation lineage in the prostate. Differentiation, 2001, 68, 270-279.	1.0	270
9	Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 221-236.	1.2	266
10	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	3.4	264
11	Cancerâ€generated lactic acid: a regulatory, immunosuppressive metabolite?. Journal of Pathology, 2013, 230, 350-355.	2.1	246
12	Translational Activation of HIF1Î± by YB-1 Promotes Sarcoma Metastasis. Cancer Cell, 2015, 27, 682-697.	7.7	226
13	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKTâ€"mTORC1 activation. Nature Medicine, 2017, 23, 1055-1062.	15.2	225
14	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. Journal of Cell Biology, 2015, 208, 913-929.	2.3	224
15	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
16	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget, 2014, 5, 764-774.	0.8	215
17	Prostatic hormonal carcinogenesis is mediated by <i>in situ</i> estrogen production and estrogen receptor alpha signaling. FASEB Journal, 2008, 22, 1512-1520.	0.2	198
18	MicroRNAs Associated with Metastatic Prostate Cancer. PLoS ONE, 2011, 6, e24950.	1.1	183

#	Article	IF	Citations
19	Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. Cancer Research, 2009, 69, 8386-8394.	0.4	179
20	Estrogen receptorâ€“Î² activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFÎ± mediated. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3123-3128.	3.3	178
21	Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death and Differentiation, 2001, 8, 192-200.	5.0	171
22	Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. International Journal of Molecular Sciences, 2020, 21, 8363.	1.8	171
23	The Androgen Receptor Negatively Regulates the Expression of c-Met: Implications for a Novel Mechanism of Prostate Cancer Progression. Cancer Research, 2007, 67, 967-975.	0.4	170
24	Patient-Derived First Generation Xenografts of Nonâ€“Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy. Clinical Cancer Research, 2010, 16, 1442-1451.	3.2	170
25	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie - International Edition, 2018, 57, 1510-1513.	7.2	168
26	The xcâ˜ cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. British Journal of Cancer, 2008, 99, 464-472.	2.9	167
27	Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate, 2005, 64, 149-159.	1.2	162
28	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161
29	Evidence That Epithelial and Mesenchymal Estrogen Receptor-Î± Mediates Effects of Estrogen on Prostatic Epithelium. Developmental Biology, 2001, 229, 432-442.	0.9	155
30	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Advanced Drug Delivery Reviews, 2014, 79-80, 222-237.	6.6	146
31	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	5.8	143
32	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology, 2017, 71, 68-78.	0.9	136
33	REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Research, 2014, 42, 999-1015.	6.5	125
34	Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 7757-7770.	1.8	122
35	Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Letters, 2021, 508, 104-114.	3.2	118
36	Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene, 2010, 29, 3593-3604.	2.6	116

#	Article	IF	Citations
37	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature, 2022, 601, 434-439.	13.7	110
38	hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO Journal, 2003, 22, 6101-6114.	3.5	108
39	Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. Clinical Cancer Research, 2015, 21, 1675-1687.	3.2	108
40	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Laboratory Investigation, 2005, 85, 1392-1404.	1.7	107
41	The x c â˜ cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemotherapy and Pharmacology, 2009, 64, 463-472.	1.1	106
42	Sex hormone-induced prostatic carcinogenesis in the Noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. , 1998, 35, 165-177.		105
43	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	105
44	Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progressionâ€"Related Changes. Clinical Cancer Research, 2006, 12, 4043-4054.	3.2	102
45	Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-Related Cancer, 2019, 26, 131-146.	1.6	98
46	Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy. Prostate, 2007, 67, 162-171.	1.2	97
47	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics, 2016, 8, 721-731.	1.0	94
48	Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics, 2015, 7, 40.	1.8	93
49	Elevated expression of the centromere proteinâ€A(CENPâ€A)â€encoding gene as a prognostic and predictive biomarker in human cancers. International Journal of Cancer, 2016, 139, 899-907.	2.3	92
50	The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer and Metastasis Reviews, 2014, 33, 1-16.	2.7	91
51	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood, 2011, 118, 3350-3358.	0.6	90
52	The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology and Oncology, 2022, 15, 18.	6.9	89
53	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Medicine, 2019, 11, 8.	3.6	88
54	<i>ASAP1</i>, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.4	87

#	Article	IF	Citations
55	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. International Journal of Cancer, 2015, 136, E27-38.	2.3	87
56	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecologic Oncology, 2005, 96, 48-55.	0.6	85
57	The<i>MCT4</i>Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 2721-2733.	3.2	84
58	Growth factors and epithelial-stromal interactions in prostate cancer development. International Review of Cytology, 2000, 199, 65-116.	6.2	82
59	miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget, 2015, 6, 6092-6104.	0.8	82
60	The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. European Urology, 2019, 76, 546-559.	0.9	82
61	Steroid hormones stimulate human prostate cancer progression and metastasis. International Journal of Cancer, 2006, 118, 2123-2131.	2.3	81
62	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	2.0	78
63	Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patientâ€derived xenograft (PDX) models. Prostate, 2018, 78, 1262-1282.	1.2	76
64	Estrogenic effects on prostatic differentiation and carcinogenesis. Reproduction, Fertility and Development, 2001, 13, 285.	0.1	74
65	<scp>ERBB</scp>4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine, 2013, 5, 1087-1102.	3.3	71
66	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology, 2014, 15, 426.	3.8	71
67	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Molecular Cancer, 2015, 14, 46.	7.9	71
68	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE, 2011, 6, e21121.	1.1	71
69	Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis, 2012, 33, 1391-1398.	1.3	69
70	Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2887-2896.	1.8	69
71	Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	69
72	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood, 2016, 127, 2203-2213.	0.6	68

#	Article	IF	Citations
73	Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. Clinical Cancer Research, 2011, 17, 783-791.	3.2	67
74	Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. Journal of Experimental and Clinical Cancer Research, 2022, 41, 105.	3.5	67
75	Molecular events in neuroendocrine prostate cancer development. Nature Reviews Urology, 2021, 18, 581-596.	1.9	65
76	ETS transcription factors as emerging drug targets in cancer. Medicinal Research Reviews, 2020, 40, 413-430.	5.0	63
77	Genistein Increases Epidermal Growth Factor Receptor Signaling and Promotes Tumor Progression in Advanced Human Prostate Cancer. PLoS ONE, 2011, 6, e20034.	1.1	60
78	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	0.9	60
79	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecologic Oncology, 2008, 110, 256-264.	0.6	59
80	The epigenetic/noncoding origin of tumor dormancy. Trends in Molecular Medicine, 2015, 21, 206-211.	3.5	59
81	Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation, 2007, 75, 871-882.	1.0	58
82	The BMP Family Member Gdf7 Is Required for Seminal Vesicle Growth, Branching Morphogenesis, and Cytodifferentiation. Developmental Biology, 2001, 234, 138-150.	0.9	57
83	The novel BETâ€CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€type prostate cancer. EMBO Molecular Medicine, 2019, 11, e10659.	3.3	56
84	GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget, 2014, 5, 451-461.	0.8	56
85	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clinical Epigenetics, 2016, 8, 16.	1.8	55
86	Targeting <scp>MCT</scp>4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Medicine, 2018, 7, 3385-3392.	1.3	55
87	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Molecular Metabolism, 2019, 25, 119-130.	3.0	55
88	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 595-608.	3.2	55
89	Decitabine-Induced Demethylation of 5â€² CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells. Neoplasia, 2008, 10, 471-480.	2.3	54
90	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience, 2018, 7, .	3.3	54

#	Article	IF	Citations
91	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. Molecular Cancer Therapeutics, 2018, 17, 2746-2755.	1.9	53
92	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for ¹⁸F-FDG Imaging of PSMA-Suppressed Tumors. Journal of Nuclear Medicine, 2020, 61, 904-910.	2.8	52
93	Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis, 2012, 33, 2558-2567.	1.3	51
94	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	5.8	51
95	Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation. Cancer Cell International, 2007, 7, 14.	1.8	48
96	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology, 2016, 10, 693-703.	2.1	48
97	Heterochromatin Protein 1Î± Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research, 2018, 78, 2691-2704.	0.4	48
98	Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate, 2003, 54, 212-219.	1.2	47
99	The immunoregulatory mechanisms of carcinoma for its survival and development. Journal of Experimental and Clinical Cancer Research, 2011, 30, 12.	3.5	47
100	Multiplexed Quantum Dot Labeling of Activated c-Met Signaling in Castration-Resistant Human Prostate Cancer. PLoS ONE, 2011, 6, e28670.	1.1	47
101	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
102	A Novel Protein Isoform of the Multicopy Human NAIP Gene Derives from Intragenic Alu SINE Promoters. PLoS ONE, 2009, 4, e5761.	1.1	47
103	Polyâ€gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1144-1153.	1.5	46
104	(Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering and Translational Medicine, 2023, 8, .	3.9	46
105	Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. Nano Today, 2022, 45, 101532.	6.2	46
106	Elevated Expression of BIRC6 Protein in Nonâ€"Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance. Journal of Thoracic Oncology, 2013, 8, 161-170.	0.5	43
107	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021, 12, 1521.	5.8	43
108	Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 77.	3.5	42

#	Article	IF	Citations
109	Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opinion on Drug Delivery, 2022, 19, 355-382.	2.4	41
110	Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate, 2013, 73, 455-466.	1.2	40
111	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget, 2015, 6, 1806-1820.	0.8	40
112	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian Journal of Andrology, 2013, 15, 301-308.	0.8	39
113	Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. Journal of Cancer, 2018, 9, 3196-3207.	1.2	39
114	Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget, 2015, 6, 21522-21532.	0.8	39
115	Drug sensitivity testing for personalized lung cancer therapy. Journal of Thoracic Disease, 2012, 4, 17-8.	0.6	38
116	Crosstalk Between Nuclear MET and SOX9/Î²-Catenin Correlates with Castration-Resistant Prostate Cancer. Molecular Endocrinology, 2014, 28, 1629-1639.	3.7	37
117	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific Reports, 2017, 7, 4079.	1.6	37
118	EZH2 inhibition: aÂpromisingÂstrategy to prevent cancer immune editing. Epigenomics, 2020, 12, 1457-1476.	1.0	37
119	The Ontogeny of the Urogenital System of the Spotted Hyena (Crocuta crocuta Erxleben)1. Biology of Reproduction, 2005, 73, 554-564.	1.2	36
120	Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. Current Cancer Drug Targets, 2006, 6, 455-489.	0.8	36
121	INPP4B suppresses prostate cancer cell invasion. Cell Communication and Signaling, 2014, 12, 61.	2.7	36
122	Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discovery Today, 2022, 27, 2181-2198.	3.2	36
123	Bisphenol A induces permanent squamous change in mouse prostatic epithelium. Differentiation, 2007, 75, 745-756.	1.0	34
124	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	1.9	34
125	Urogenital system of the spotted hyena (Crocuta crocuta Erxleben): A functional histological study. Journal of Morphology, 2003, 256, 205-218.	0.6	33
126	CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. American Journal of Pathology, 2011, 179, 2100-2107.	1.9	33

#	Article	IF	Citations
127	BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS ONE, 2013, 8, e55837.	1.1	33
128	Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis, 2013, 34, 257-267.	1.3	32
129	Development of metastatic and nonâ€metastatic tumor lines from a patient's prostate cancer specimenâ€”identification of a small subpopulation with metastatic potential in the primary tumor. Prostate, 2010, 70, 1636-1644.	1.2	31
130	The<i>BIRC6</i>gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget, 2014, 5, 6896-6908.	0.8	31
131	Collagen Triple Helix Repeat Containing 1 Promotes Melanoma Cell Adhesion and Survival. Journal of Cutaneous Medicine and Surgery, 2011, 15, 103-110.	0.6	30
132	Next generation patient-derived prostate cancer xenograft models. Asian Journal of Andrology, 2014, 16, 407.	0.8	30
133	Rescue of Embryonic Epithelium Reveals That the Homozygous Deletion of the Retinoblastoma Gene Confers Growth Factor Independence and Immortality but Does Not Influence Epithelial Differentiation or Tissue Morphogenesis. Journal of Biological Chemistry, 2002, 277, 44475-44484.	1.6	29
134	Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angewandte Chemie, 2018, 130, 1526-1529.	1.6	29
135	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patientâ€derived, advanced prostate cancer tissue xenograft model. Molecular Oncology, 2014, 8, 311-322.	2.1	28
136	<i>BIRC6</i> Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 1542-1551.	3.2	28
137	The long noncoding <scp>RNA </scp><i><scp>HORAS</scp>5</i> mediates castrationâ€resistant prostate cancer survival by activating the androgen receptor transcriptional program. Molecular Oncology, 2019, 13, 1121-1136.	2.1	28
138	Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer. Journal of Cellular Biochemistry, 2019, 120, 11383-11389.	1.2	28
139	PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. Gene, 2020, 744, 144608.	1.0	28
140	Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor. Sarcoma, 2010, 2010, 1-7.	0.7	26
141	A synopsis of prostate organoid methodologies, applications, and limitations. Prostate, 2020, 80, 518-526.	1.2	26
142	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Journal of Physical Education and Sports Management, 2017, 3, a001487.	0.5	25
143	SRRM4 gene expression correlates with neuroendocrine prostate cancer. Prostate, 2019, 79, 96-104.	1.2	25
144	Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Differentiation, 2016, 91, 15-19.	1.0	24

#	Article	IF	Citations
145	An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-8.	0.5	23
146	Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. Cancer Letters, 2010, 292, 176-185.	3.2	22
147	Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate, 2011, 71, 675-681.	1.2	22
148	Epithelial immune cell-like transition (EIT): A proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation, 2012, 83, 293-298.	1.0	22
149	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. Epigenomics, 2015, 7, 757-765.	1.0	22
150	The evolutionarily conserved long nonâ€coding RNA <i>LINC00261</i> drives neuroendocrine prostate cancer proliferation and metastasis <i>via</i> distinct nuclear and cytoplasmic mechanisms. Molecular Oncology, 2021, 15, 1921-1941.	2.1	22
151	The role of mRNA splicing in prostate cancer. Asian Journal of Andrology, 2014, 16, 515.	0.8	21
152	Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma. Cancers, 2020, 12, 1568.	1.7	21
153	Deletion of Leucine Zipper Tumor Suppressor 2 (Lzts2) Increases Susceptibility to Tumor Development. Journal of Biological Chemistry, 2013, 288, 3727-3738.	1.6	20
154	Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 17-24.	1.6	20
155	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes and Cancer, 2017, 7, 340-354.	0.6	20
156	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology, 2018, 73, 949-960.	0.9	19
157	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. European Urology, 2019, 76, 157-166.	0.9	19
158	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia, 2020, 22, 253-262.	2.3	19
159	SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nature Communications, 2021, 12, 5716.	5.8	19
160	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget, 2017, 8, 9617-9633.	0.8	18
161	LncRNA <i>HORAS5</i> promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics, 2020, 12, 1123-1138.	1.0	17
162	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. PLoS ONE, 2017, 12, e0182818.	1.1	17

#	Article	IF	Citations
163	Oncogenes and tumor suppressor genes in prostate cancer: a review. Urologic Oncology: Seminars and Original Investigations, 1997, 3, 41-46.	0.8	16
164	Metabolic heterogeneity signature of primary treatment-naÃ¯ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	0.8	16
165	Molecular analysis and characterization of PrEc, commercially available prostate epithelial cells. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 33-39.	0.7	15
166	Genistein versus ICI 182, 780: An ally or enemy in metastatic progression of prostate cancer. Prostate, 2013, 73, 1747-1760.	1.2	15
167	Transmembrane and Coiled-Coil Domain Family 1 Is a Novel Protein of the Endoplasmic Reticulum. PLoS ONE, 2014, 9, e85206.	1.1	15
168	Systematic Identification and Characterization of RNA Editing in Prostate Tumors. PLoS ONE, 2014, 9, e101431.	1.1	15
169	Tâ€type calcium channels drive the proliferation of androgenâ€receptor negative prostate cancer cells. Prostate, 2019, 79, 1580-1586.	1.2	14
170	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. Nature Communications, 2021, 12, 5779.	5.8	14
171	Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. Frontiers in Bioscience - Scholar, 2016, 8, 44-55.	0.8	13
172	Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. Cells, 2020, 9, 1398.	1.8	13
173	Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	13
174	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. Asian Journal of Urology, 2016, 3, 195-202.	0.5	12
175	Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. British Journal of Cancer, 2018, 118, 802-812.	2.9	12
176	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. International Journal of Endocrine Oncology, 2019, 6, IJE20.	0.4	12
177	<i>HAR1</i>: an insight into lncRNA genetic evolution. Epigenomics, 2021, 13, 1831-1843.	1.0	12
178	Androgen receptor (AR) antagonism triggers acute succinateâ€mediated adaptive responses to reactivate AR signaling. EMBO Molecular Medicine, 2021, 13, e13427.	3.3	11
179	Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification. Asian Journal of Andrology, 2014, 16, 545.	0.8	11
180	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10

#	Article	IF	Citations
181	Patient-derived xenograft models of neuroendocrine prostate cancer. Cancer Letters, 2022, 525, 160-169.	3.2	10
182	Modeling Androgen Deprivation Therapyâ€"Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	1.5	10
183	The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphologic and functional cytodifferentiation of dunning prostatic adenocarcinoma: Roles of growth factors and proto-oncogenes. Urologic Oncology: Seminars and Original Investigations, 1997, 3, 85-93.	0.8	9
184	Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts. Frontiers in Genetics, 2018, 9, 232.	1.1	9
185	Establishment and characterization of a novel treatmentâ€related neuroendocrine prostate cancer cell line KUCaP13. Cancer Science, 2021, 112, 2781-2791.	1.7	9
186	Changes in Serum and Tissue Zinc Levels in Sex Hormone-Induced Prostatic Carcinogenesis in the Noble Rat. Tumor Biology, 2000, 21, 328-336.	0.8	8
187	Lessons from in-vivo models of castration-resistant prostate cancer. Current Opinion in Urology, 2013, 23, 214-219.	0.9	8
188	Aneustat (OMN54) has aerobic glycolysisâ€inhibitory activity and also immunomodulatory activity as indicated by a firstâ€generation PDX prostate cancer model. International Journal of Cancer, 2018, 143, 419-429.	2.3	8
189	Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?. Epigenomics, 2018, 10, 1259-1261.	1.0	7
190	A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines. PLoS ONE, 2014, 9, e103050.	1.1	7
191	Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells. Frontiers in Cellular and Infection Microbiology, 2019, 9, 25.	1.8	6
192	Chromoplexy: a new paradigm in genome remodeling and evolution. Asian Journal of Andrology, 2013, 15, 711-712.	0.8	6
193	TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis. Neoplasma, 2018, 65, 815-821.	0.7	6
194	Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep ImmuneÂ®) in TRAMP Mice. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-12.	0.5	5
195	Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.. Journal of Clinical Oncology, 2019, 37, 62-62.	0.8	4
196	Rescue and Isolation of Rb-deficient Prostate Epithelium by Tissue Recombination. , 2003, 218, 17-34.		3
197	<scp>GRB10</scp> sustains <scp>AR</scp> activity by interacting with <scp>PP2A</scp> in prostate cancer cells. International Journal of Cancer, 2021, 148, 469-480.	2.3	3
198	Response to Savaskan NE et al. â€œThe x cystine/glutamate antiporterâ€"A potential target for therapy of cancer and other diseases: Yet another cytotoxic anticancer approach?â€. Journal of Cellular Physiology, 2009, 220, 533-534.	2.0	2

#	ARTICLE	IF	CITATIONS
199	MOLECULAR ANALYSIS AND CHARACTERIZATION OF PrEC, COMMERCIALLY AVAILABLE PROSTATE EPITHELIAL CELLS. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 33.	0.7	1
200	Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy. Cancer Drug Discovery and Development, 2017, , 17-29.	0.2	1
201	Immuno-oncology of Dormant Tumours. Cancer Drug Discovery and Development, 2017, , 51-60.	0.2	1
202	Long Non-coding RNAs and Cancer Cellsâ€™ Drug Resistance: An Unexpected Connection. RNA Technologies, 2020, , 167-198.	0.2	1
203	Prospectives. Molecular and Translational Medicine, 2017, , 193-200.	0.4	0
204	Patient-Derived Tumor Xenografts: Historical Background. Molecular and Translational Medicine, 2017, , 1-9.	0.4	0
205	Hormonal Carcinogenesis: The Role of Estrogens. , 2017, , 307-322.		0
206	BIRC6 (Baculoviral IAP repeat-containing 6). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .	0.1	0
207	ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development. Prostate Cancer and Prostatic Diseases, 2021, 24, 775-785.	2.0	0
208	The Nonâ€Coding Transcriptome as a Dynamic Regulator of Prostate Cancer Metastasis. FASEB Journal, 2015, 29, 221.3.	0.2	0
209	Abstract 1834: Semaphorin 3C is an androgen receptor-regulated gene. , 2016, , .		0
210	Abstract 4420: Elevated glycolytic gene signature in patient-derived neuroendocrine prostate cancer xenograft models and its clinical relevance. , 2017, , .		0
211	Abstract 3189: Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer. , 2017, , .		0
212	Abstract 3410: Copy number estimation from whole-exome sequencing in tumors. , 2018, , .		0
213	Abstract 1918: Patient-derived hormone-naive prostate cancer xenograft models revealGRB10as an AR-repressed gene driving the development of castration-resistant prostate cancer. , 2018, , .		0
214	Abstract 773: A heterochromatin gene signature unveils HP1Î± mediating neuroendocrine prostate cancer development and aggressiveness. , 2018, , .		0
215	Using NEPC cell NCI-H660 for in vitro assays. Protocol Exchange, 0, , .	0.3	0
216	Abstract 3698: Conditionally reprogrammed cells from patient-derived xenograft to model neuroendocrine prostate cancer development. , 2019, , .		0

#	Article	IF	Citations
217	Targeting HP1-alpha for prevention and treatment of neuroendocrine prostate cancer. Oncology Abstracts, 0, , .	0.0	0
218	Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer. Cells, 2022, 11, 1550.	1.8	0